Syndax Pharmaceuticals, Inc.SNDXNASDAQ
LOADING
|||
Switch Symbol:
Operating Income Growth Trend
Above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
17.20%
↑ 273% above average
Average (39q)
4.61%
Historical baseline
Range
High:577.98%
Low:-138.49%
CAGR
-0.4%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 17.20% |
| Q2 2025 | 17.20% |
| Q1 2025 | 13.08% |
| Q4 2024 | -7.58% |
| Q3 2024 | -20.70% |
| Q2 2024 | 6.66% |
| Q1 2024 | -2.07% |
| Q4 2023 | -38.24% |
| Q3 2023 | -13.44% |
| Q2 2023 | -7.96% |
| Q1 2023 | -9.47% |
| Q4 2022 | -19.61% |
| Q3 2022 | 6.85% |
| Q2 2022 | -2.35% |
| Q1 2022 | -138.49% |
| Q4 2021 | 577.98% |
| Q3 2021 | 10.31% |
| Q2 2021 | 17.78% |
| Q1 2021 | -36.77% |
| Q4 2020 | -0.04% |
| Q3 2020 | -19.52% |
| Q2 2020 | -10.00% |
| Q1 2020 | -6.30% |
| Q4 2019 | -8.03% |
| Q3 2019 | 14.47% |
| Q2 2019 | -3.80% |
| Q1 2019 | 23.39% |
| Q4 2018 | -8.36% |
| Q3 2018 | 5.86% |
| Q2 2018 | 4.05% |
| Q1 2018 | -1.34% |
| Q4 2017 | -26.18% |
| Q3 2017 | -11.59% |
| Q2 2017 | -5.05% |
| Q1 2017 | -18.27% |
| Q4 2016 | 26.89% |
| Q3 2016 | -76.49% |
| Q2 2016 | 1.36% |
| Q1 2016 | -87.07% |
| Q4 2015 | 20.13% |